ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Fujifilm to pump $1.6bn into biopharma in U.S. and Europe

Japan group to nearly quadruple capacity to meet rising demand for cancer drugs

Fujifilm will add equipment to its contract biopharmaceutical plants, such as this one in Denmark. (Photo courtesy of Fujifilm)

TOKYO -- Japan's Fujifilm Holdings will spend $1.6 billion (about 200 billion yen) to nearly quadruple its capacity for biopharmaceutical products by upgrading U.S. and European plants, Nikkei has learned.

Fujifilm intends to boost its contract manufacturing of biopharmaceuticals for startups and large drug companies that aim to develop highly effective treatments for cancer, diabetes and other diseases.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more